{"id":3783,"date":"2019-08-30T10:36:55","date_gmt":"2019-08-30T07:36:55","guid":{"rendered":"https:\/\/info.e-med.co.il\/utiproplus\/?p=3783"},"modified":"2023-12-13T10:49:53","modified_gmt":"2023-12-13T08:49:53","slug":"xyloglucan-hibiscus-and-propolis-to-reduce-symptoms-and-antibiotics-use-in-recurrent-utis-a-prospective-study","status":"publish","type":"post","link":"https:\/\/info.e-med.co.il\/utiproplus\/2019\/08\/30\/xyloglucan-hibiscus-and-propolis-to-reduce-symptoms-and-antibiotics-use-in-recurrent-utis-a-prospective-study\/","title":{"rendered":"Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study"},"content":{"rendered":"

Abstract<\/h2>\n
\n
Aim:<\/b>\u00a0To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs).\u00a0Patients & methods:<\/b>\u00a0Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment.\u00a0Results:<\/b>\u00a0At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1\u00a0vs 98.7; QoL 94.2 vs 99.1; p\u00a0<\u00a00.001). A statistically significant reduction in antibiotic use was reported.\u00a0Conclusion:<\/b>\u00a0This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.<\/section>\n
<\/section>\n<\/div>\n

\u05dc\u05d4\u05de\u05e9\u05da \u05e7\u05e8\u05d9\u05d0\u05d4<\/a><\/p>\n

Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study<\/a><\/div>\n
Tommaso Cai<\/span>,\u00a0Irene Tamanini<\/span>,\u00a0Andrea Cocci<\/span>,\u00a0Fabrizio di Maida<\/span>,\u00a0Patrizio Caciagli<\/span>,\u00a0Serena Migno<\/span>,\u00a0Liliana Mereu<\/span>,\u00a0Saverio Tateo<\/span>,\u00a0Gianni Malossini<\/span>,\u00a0Alessandro Palmieri<\/span>,\u00a0Paolo Verze<\/span>,\u00a0Vincenzo Mirone<\/span>, and\u00a0Truls E Bjerklund Johansen<\/span><\/div>\n

Future Microbiology<\/span>\u00a02019<\/span>\u00a014<\/span>:12<\/span>,\u00a01013-1021<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Abstract Aim:\u00a0To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs).\u00a0Patients & methods:\u00a0Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological […]<\/p>\n","protected":false},"author":2,"featured_media":3785,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,6,3],"tags":[],"class_list":["post-3783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-en","category-research","category-updates-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t